New drug combo aims to tame stubborn high blood pressure

NCT ID NCT07704697

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding amlodipine to Sacubitril/Allisartan can lower blood pressure more effectively than Sacubitril/Allisartan alone in people with essential hypertension. Participants whose blood pressure remains high after four weeks on Sacubitril/Allisartan are randomly assigned to receive either the combination or continue with Sacubitril/Allisartan for 12 weeks. The main goal is to see how much systolic blood pressure drops from the start of the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of Sacubitril/Allisartan and Amlodipine
What this could lead to
If successful, this combination could offer a new treatment option for people with high blood pressure that is not well controlled by Sacubitril/Allisartan alone.
What could go wrong
This is a 12-week study, so long-term safety and effectiveness are not yet known. The results may not apply to all patients with hypertension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.